NL301103I1 - tagraxofusp - Google Patents
tagraxofuspInfo
- Publication number
- NL301103I1 NL301103I1 NL301103C NL301103C NL301103I1 NL 301103 I1 NL301103 I1 NL 301103I1 NL 301103 C NL301103 C NL 301103C NL 301103 C NL301103 C NL 301103C NL 301103 I1 NL301103 I1 NL 301103I1
- Authority
- NL
- Netherlands
- Prior art keywords
- tagraxofusp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84347106P | 2006-09-07 | 2006-09-07 | |
US93277207P | 2007-06-01 | 2007-06-01 | |
EP07837840.3A EP2063907B1 (en) | 2006-09-07 | 2007-09-07 | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
PCT/US2007/019481 WO2008030539A2 (en) | 2006-09-07 | 2007-09-07 | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
NL301103I1 true NL301103I1 (nl) | 2021-06-17 |
NL301103I2 NL301103I2 (nl) | 2021-08-02 |
Family
ID=39157851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301103C NL301103I2 (nl) | 2006-09-07 | 2021-05-12 | tagraxofusp |
Country Status (17)
Country | Link |
---|---|
US (7) | US7763242B2 (nl) |
EP (3) | EP3207941B3 (nl) |
JP (6) | JP5550905B2 (nl) |
AU (1) | AU2007293047B2 (nl) |
CA (5) | CA2923381A1 (nl) |
CY (2) | CY1119654T1 (nl) |
DK (2) | DK3207941T6 (nl) |
ES (2) | ES2781402T7 (nl) |
FR (1) | FR21C1017I2 (nl) |
HU (2) | HUE048356T2 (nl) |
LT (2) | LT3207941T (nl) |
LU (1) | LUC00206I2 (nl) |
NL (1) | NL301103I2 (nl) |
PL (2) | PL3207941T6 (nl) |
PT (1) | PT3207941T (nl) |
SI (1) | SI3207941T1 (nl) |
WO (1) | WO2008030539A2 (nl) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2545942C (en) | 2003-11-14 | 2012-07-10 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
CA2923381A1 (en) | 2006-09-07 | 2008-03-13 | Arthur E. Frankel | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
WO2010027802A2 (en) | 2008-08-25 | 2010-03-11 | New York University | Methods for treating diabetic wounds |
WO2010031185A1 (en) * | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
CN103002913B (zh) * | 2010-02-17 | 2015-12-16 | Csl有限公司 | 靶向产生i型干扰素的细胞的组合物和方法 |
EP4056193A1 (en) | 2010-06-17 | 2022-09-14 | New York University | Therapeutic and cosmetic uses and applications of calreticulin |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
SG10201506782XA (en) | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
AU2011295715B9 (en) | 2010-09-03 | 2017-02-23 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
NZ728016A (en) | 2010-12-08 | 2020-06-26 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
ES2741936T3 (es) | 2012-02-24 | 2020-02-12 | Abbvie Stemcentrx Llc | Anticuerpos anti-SEZ6 y procedimientos de uso |
PL2817338T3 (pl) | 2012-02-24 | 2017-12-29 | Abbvie Stemcentrx Llc | Modulatory DLL3 i sposoby zastosowania |
EP3556400A1 (en) | 2013-02-22 | 2019-10-23 | AbbVie Stemcentrx LLC | Method of making antidll3-antibody pbd conjugates |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
CN105792836A (zh) | 2013-08-28 | 2016-07-20 | 施特姆森特克斯股份有限公司 | 新型sez6调节剂以及应用方法 |
WO2015051302A1 (en) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions and methods for treating cancers |
CN105813650A (zh) | 2013-11-06 | 2016-07-27 | 施特姆森特克斯股份有限公司 | 新型抗-密蛋白抗体和使用方法 |
WO2015089449A2 (en) | 2013-12-12 | 2015-06-18 | Stem Centrx, Inc. | Novel anti-dpep3 antibodies and methods of use |
MX2016010677A (es) | 2014-02-21 | 2017-04-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. |
LT3137114T (lt) | 2014-04-30 | 2021-03-25 | Pfizer Inc. | Anti-ptk7 antikūnų ir vaistų konjugatai |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
WO2017184942A1 (en) | 2016-04-21 | 2017-10-26 | Abbvie Stemcentrx Llc | Novel anti-bmpr1b antibodies and methods of use |
CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
TW201936190A (zh) | 2017-10-30 | 2019-09-16 | 加拿大商艾普托斯生物科學公司 | 用於治療癌症之芳基咪唑 |
WO2019210179A1 (en) | 2018-04-27 | 2019-10-31 | Stemline Therapeutics, Inc. | Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3) |
WO2019227222A1 (en) * | 2018-05-30 | 2019-12-05 | The Governing Council Of The University Of Toronto | Methods and kits for identifying a protein associated with receptor-ligand interactions |
EP3873476A1 (en) * | 2018-10-31 | 2021-09-08 | Stemline Therapeutics, Inc. | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
WO2020112642A1 (en) | 2018-11-30 | 2020-06-04 | Stemline Therapeutics, Inc. | Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate |
EP4061967A1 (en) * | 2019-11-21 | 2022-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml) |
MX2023006805A (es) | 2020-12-10 | 2023-07-06 | Stemline Therapeutics Inc | Formulacion liofilizada mejorada. |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU573529B2 (en) | 1982-05-12 | 1988-06-16 | President And Fellows Of Harvard College | Hybrid proteins |
US5080898A (en) | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
CA2076678C (en) | 1990-03-02 | 1999-09-28 | Diane Williams | Improved chimeric toxins |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
DE4121547A1 (de) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | Mehrschichtisolierfolie |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE4140121C2 (de) | 1991-12-05 | 1994-06-30 | Manfred Mueller | Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
AU5965296A (en) * | 1995-05-31 | 1996-12-18 | Regents Of The University Of Minnesota | Recombinant polypeptide cytotoxins for cancer treatment |
WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
US20040013664A1 (en) | 1997-01-14 | 2004-01-22 | Gentz Reiner L. | Tumor necrosis factor receptors 6 alpha & 6 beta |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
WO2001040308A1 (en) | 1999-12-03 | 2001-06-07 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Dendritic cell-specific antibodies |
AU2001250030B2 (en) | 2000-03-06 | 2004-11-25 | University Of Kentucky Research Foundation | Use of a compound that selectively binds to CD123 to impair hematologic cancer progenitor cell |
MXPA03007878A (es) | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
US20030068320A1 (en) | 2001-03-02 | 2003-04-10 | Christine Dingivan | Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
AU2014201901B2 (en) | 2006-09-07 | 2016-05-05 | Scott & White Healthcare | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
CA2923381A1 (en) * | 2006-09-07 | 2008-03-13 | Arthur E. Frankel | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
US20150038679A1 (en) | 2012-02-29 | 2015-02-05 | Ambrx, Inc. | Interleukin-3 Polypeptide Conjugates and Their Uses |
-
2007
- 2007-09-07 CA CA2923381A patent/CA2923381A1/en not_active Abandoned
- 2007-09-07 ES ES17151480T patent/ES2781402T7/es active Active
- 2007-09-07 PL PL17151480T patent/PL3207941T6/pl unknown
- 2007-09-07 DK DK17151480.5T patent/DK3207941T6/da active
- 2007-09-07 AU AU2007293047A patent/AU2007293047B2/en active Active
- 2007-09-07 DK DK07837840.3T patent/DK2063907T3/da active
- 2007-09-07 CA CA2698595A patent/CA2698595C/en active Active
- 2007-09-07 CA CA3007075A patent/CA3007075C/en active Active
- 2007-09-07 WO PCT/US2007/019481 patent/WO2008030539A2/en active Application Filing
- 2007-09-07 EP EP17151480.5A patent/EP3207941B3/en active Active
- 2007-09-07 ES ES07837840.3T patent/ES2646545T3/es active Active
- 2007-09-07 LT LTEP17151480.5T patent/LT3207941T/lt unknown
- 2007-09-07 CA CA3053981A patent/CA3053981C/en active Active
- 2007-09-07 CA CA3153438A patent/CA3153438C/en active Active
- 2007-09-07 PL PL07837840T patent/PL2063907T3/pl unknown
- 2007-09-07 EP EP19159793.9A patent/EP3520806B1/en active Active
- 2007-09-07 EP EP07837840.3A patent/EP2063907B1/en active Active
- 2007-09-07 JP JP2009527415A patent/JP5550905B2/ja active Active
- 2007-09-07 HU HUE17151480A patent/HUE048356T2/hu unknown
- 2007-09-07 US US11/899,747 patent/US7763242B2/en active Active
- 2007-09-07 SI SI200732148T patent/SI3207941T1/sl unknown
- 2007-09-07 PT PT171514805T patent/PT3207941T/pt unknown
-
2009
- 2009-02-09 US US12/368,048 patent/US8470307B2/en active Active
-
2013
- 2013-05-17 US US13/896,923 patent/US9181317B2/en active Active
-
2014
- 2014-04-01 JP JP2014075847A patent/JP5902223B2/ja active Active
-
2015
- 2015-07-17 US US14/802,398 patent/US9631006B2/en active Active
-
2016
- 2016-03-09 JP JP2016045210A patent/JP6336500B2/ja active Active
-
2017
- 2017-03-10 US US15/455,420 patent/US10259853B2/en active Active
- 2017-11-03 CY CY20171101153T patent/CY1119654T1/el unknown
-
2018
- 2018-05-02 JP JP2018088719A patent/JP6654660B2/ja active Active
-
2019
- 2019-02-08 US US16/271,456 patent/US11130792B2/en active Active
-
2020
- 2020-01-30 JP JP2020013230A patent/JP2020079260A/ja active Pending
- 2020-03-23 CY CY20201100271T patent/CY1123035T1/el unknown
-
2021
- 2021-04-22 HU HUS2100013C patent/HUS2100013I1/hu unknown
- 2021-05-11 FR FR21C1017C patent/FR21C1017I2/fr active Active
- 2021-05-12 NL NL301103C patent/NL301103I2/nl unknown
- 2021-05-12 LU LU00206C patent/LUC00206I2/en unknown
- 2021-05-12 LT LTPA2021507C patent/LTC3207941I2/lt unknown
- 2021-08-25 US US17/411,947 patent/US20220235108A1/en active Pending
-
2022
- 2022-02-15 JP JP2022020917A patent/JP2022065089A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301103I1 (nl) | tagraxofusp | |
DE602006019782D1 (de) | Kapselperforationsmodul | |
DE602007002544D1 (de) | Nuancierungsmittel | |
DE602007008423D1 (de) | Flüssigkeitshärtung | |
DE602007003893D1 (de) | Kippambossanordnung | |
DE602007009650D1 (de) | Spiroindolinonderivate | |
DE602007006947D1 (de) | Pyridopyrimidinonderivate | |
DE602007000258D1 (de) | Kassetteneinspannmechanismus | |
DE602006020192D1 (de) | Riemenscheibenanorndung | |
DE602007001280D1 (de) | Getränkeextraktor | |
AT504580A3 (de) | Scan-einrichtung | |
DE602007008400D1 (de) | Kaliummonopersulfatlösungen | |
DE602007010359D1 (de) | Azaspiroderivate | |
DE602006019150D1 (de) | Riemenscheibenanorndung | |
ATE546437T1 (de) | Aminomethyl-4-imidazole | |
DE502007000218D1 (de) | nsetzungen | |
DE502007002453D1 (de) | Kunstoffverdichtergehäuse | |
DE602007000501D1 (de) | Breitbandrichtkoppler | |
DE602007004080D1 (de) | Tintenstrahlaufnehmer | |
DE602007007460D1 (de) | Sehkrafttestsystem | |
DE602006016174D1 (de) | Blisterverpackungsverfahren | |
DE502007000361D1 (de) | Stanznieteinheit | |
DE502007001629D1 (de) | Rfahren | |
DE602007000333D1 (de) | Napfbefestigungsvorrichtung | |
DE102006045567A8 (de) | Crimpstabilisierung |